Tango Therapeutics, Inc.
TNGX
Rank in Stocks
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Share Price
$27.18
Last synced: 2026-07-31
Market Cap
$3.38B
Change (1 day)
-1.41%
Change (1 year)
197.05%
Country
US
Trade Tango Therapeutics, Inc. (TNGX)
Category
Healthcare
Stock split history for Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. stock (symbol: TNGX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One TNGX share bought prior to Oct 20, 2026 would equal to 0 TNGX shares today.
The most recent stock split occurred on Oct 20, 2026.
One TNGX share bought prior to Oct 20, 2026 would equal to 0 TNGX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
